Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
purinostat mesylate + fulvestrant
- Development stage
- Phase 2
- Lead developer
- State Key Laboratory of Biotherapy
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
**Purinostat mesylate + fulvestrant** is a combination therapy under clinical investigation for advanced solid tumors. Purinostat mesylate is a highly selective and active inhibitor of histone deacetylases (HDAC) class I and IIb, showing preclinical efficacy against leukemia stem cells and enhancing anti-cancer effects through epigenetic modulation. Fulvestrant is a selective estrogen receptor degrader (SERD) used in hormone receptor-positive (HR+) advanced breast cancer to block estrogen signaling by promoting estrogen receptor degradation. The combination aims to target both epigenetic regulation and hormone receptor signaling, potentially overcoming endocrine resistance in solid tumors, particularly HR+ breast cancer.
- Other names
- PM + fulvestrant
02
Targets
ESR1 (ERα)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC6 (Histone deacetylase 6)HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on purinostat mesylate + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on purinostat mesylate + fulvestrant.